PABLO
ROJO CONEJO
Profesor asociado de Ciencias de la Salud
University College London
Londres, Reino UnidoPublicaciones en colaboración con investigadores/as de University College London (24)
2024
-
Effectiveness and Safety of Direct-acting Antivirals for Treatment of Adolescents With HCV/HIV Coinfection: Real-world Data From Europe
Pediatric Infectious Disease Journal, Vol. 43, Núm. 5, pp. E155-E159
2023
-
Adeno-associated virus 2 infection in children with non-A–E hepatitis
Nature, Vol. 617, Núm. 7961, pp. 555-563
-
Effective early antiretroviral therapy in perinatal-HIV infection reduces subsequent plasma inflammatory profile
Pediatric Research, Vol. 94, Núm. 5, pp. 1667-1674
-
Genomic investigations of unexplained acute hepatitis in children
Nature, Vol. 617, Núm. 7961, pp. 564-573
-
The hard part we often forget: providing care to children and adolescents with advanced HIV disease
Journal of the International AIDS Society, Vol. 26, Núm. 3, pp. e26041
2022
2021
-
ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing
BMC infectious diseases, Vol. 21, Núm. 1, pp. 5
-
Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients with Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE
Clinical Infectious Diseases, Vol. 73, Núm. 2, pp. 195-202
2020
-
Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: A systematic review
Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 12, pp. 3433-3457
-
Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial
The Lancet HIV, Vol. 7, Núm. 8, pp. e533-e544
-
The HIV drug optimization agenda: promoting standards for earlier investigation and approvals of antiretroviral drugs for use in adolescents living with HIV
Journal of the International AIDS Society
2019
-
Plasma lipid profiles discriminate bacterial from viral infection in febrile children
Scientific Reports, Vol. 9, Núm. 1
-
Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list
The Lancet HIV, Vol. 6, Núm. 9, pp. e623-e631
-
Reduced Time to Suppression among Neonates with HIV Initiating Antiretroviral Therapy Within 7 Days after Birth
Journal of Acquired Immune Deficiency Syndromes, Vol. 82, Núm. 5, pp. 483-490
2018
-
Early and highly suppressive antiretroviral therapy are main factors associated with low viral reservoir in European perinatally HIV-infected children
Journal of Acquired Immune Deficiency Syndromes
-
Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation
Journal of the International AIDS Society, Vol. 21, Núm. 11
2017
-
Erratum to: Safety of zidovudine/lamivudine scored tablets in children with HIV infection in Europe and Thailand (European Journal of Clinical Pharmacology, (2017), 73, 4, (463-468), 10.1007/s00228-016-2182-2)
European Journal of Clinical Pharmacology
-
Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe
HIV Medicine, Vol. 18, Núm. 3, pp. 171-180
-
Optimizing research to speed up availability of pediatric antiretroviral drugs and formulations
Clinical Infectious Diseases, Vol. 64, Núm. 11, pp. 1597-1603
2016
-
Safety of darunavir and atazanavir in HIV-infected children in Europe and Thailand
Antiviral Therapy, Vol. 21, Núm. 4, pp. 353-358